Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317240

SCHEMBL25317240

SCHEMBL25317240

CC(C)(C)OC(=O)N1CCC2(CC1)C(=O)N(COCC[Si](C)(C)C)c1ccc(OC(F)F)cc12

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 1/20 0.35
▸ BACE1 P56817 2/20 0.35
▸ ALK Q9UM73 1/20 0.35
▸ NAMPT P43490 4/20 0.34
▸ GPR119 Q8TDV5 4/20 0.34
▸ RET P07949 1/20 0.34
▸ CTSD P07339 1/20 0.34
▸ CTSE P14091 1/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ OPRD1 P41143 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507038 1.00 TACR1 (0.35) TACR1BACE1ALKNAMPTGPR119
SCHEMBL25316799 0.89 BACE1 (0.35) BACE1CTSD
SCHEMBL30506821 0.87 ESR2 (0.39) TACR1BACE1NAMPTGPR119HRH3
SCHEMBL25315913 0.87 ESR2 (0.39) TACR1BACE1NAMPTGPR119HRH3
SCHEMBL25317620 0.86 DDR1 (0.41) TACR1BACE1ALKNAMPT
SCHEMBL31436447 0.86 DDR1 (0.41) NAMPTOPRD1OPRK1
SCHEMBL30506793 0.86 DDR1 (0.41) TACR1BACE1ALKNAMPT
SCHEMBL25315612 0.82 PRMT5 (0.42) TACR1BACE1NAMPTGPR119OPRD1
SCHEMBL15699763 0.76 NAMPT (0.37) ALKNAMPTGPR119OPRD1OPRK1
SCHEMBL25316481 0.75 OPRL1 (0.36) OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR TACR1 2658/4885BACE1 35/4885ALK 4587/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 TACR1 2608/4885BACE1 30/4885ALK 4572/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR TACR1 2658/4885BACE1 35/4885ALK 4587/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 TACR1 2608/4885BACE1 30/4885ALK 4572/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 TACR1 2608/4885BACE1 30/4885ALK 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.